Relative Bioavailability of a Single Dose 20 mg BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) Following Oral Administration to Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Phase I Study)
Latest Information Update: 28 Jun 2014
At a glance
- Drugs Afatinib (Primary)
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Glioma; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 28 Jun 2014 New trial record